Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-23
2011-08-23
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
08003646
ABSTRACT:
This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABA-A receptor antagonist and/or a α2, α3 and α5 GABA-A receptor agonist.
REFERENCES:
patent: 6221335 (2001-04-01), Foster
patent: 6255305 (2001-07-01), Broughton et al.
patent: 6440710 (2002-08-01), Keinan et al.
patent: 6500828 (2002-12-01), Carling et al.
patent: 6603008 (2003-08-01), Ando et al.
patent: 7517990 (2009-04-01), Ito et al.
patent: 2002/0165217 (2002-11-01), Howard
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 2007/0197695 (2007-08-01), Potyen et al.
patent: 2008/0103122 (2008-05-01), Veltri
patent: WO-95/26325 (1995-10-01), None
patent: WO-2007/118651 (2007-10-01), None
McMahon et al., Psychopharmacology, (2007), 192(1), 135-145.
Foster, A.B., “Deuterium isotope effects in studies of drug metabolism”, TIPS 524-527 (Dec. 1984).
Gouyette, A., Biomedical and Environmental Mass Spectrometry, vol. 15, 243-247 (1988).
Cherrah, Y. et al., Biomedical and Environmental Mass Spectrometry, vol. 14, Issue 11, pp. 653-657 (1987).
Dyck, L.E. et al., Journal of Neurochemistry, vol. 46, Issue 2, pp. 399-404 (1986).
Tonn, G.R., et al., Biological Mass Spectrometry, vol. 22, Issue 11, pp. 633-642 (1993).
Haskins, N.J., Biomedical Spectrometry, vol. 9, Issue 7, pp. 269-277 (1982).
Wolen, R.L., J. Clin. Pharmacology 26: 419-424 (1986).
Pieniaszek, H.J. et al., J. Clin. Pharmacol. 39:817-825 (1999).
Honma, S. et al., Drug Metab Dispos 15(4): 551-559 (1987).
Browne, T.R., Journal of Clinical Pharmacology 38: 213-220 (1998).
Baillie, T.A., Pharmacology Rev. 33:81-132 (1981).
Foster, A.B., Adv Drug Res, 14:1-40 (1985).
Fisher et al., The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism. Curr Opin Drug Discov Devel. 9(1): 101-9 (2006).
Kushner, et al., “Pharmacological uses and perspectives of heavy water and deuterated compounds”, Can. J. Physiol. Pharmacol. 77: 79-88 (1999).
Scott-Stevens et al., “Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417”, Biopharm. Drug Dispos., vol. 26, No. 1, pp. 13-20 (2005).
International Preliminary Report on Patentability for corresponding PCT Application No. PCT/US2009/055427 (Dated Mar. 1, 2011).
International Search Report for corresponding PCT Application No. PCT/US2009/055427 (Dated Oct. 15, 2009).
Written Opinion for corresponding PCT Application No. PCT/US2009/055427 (Dated Oct. 15, 2009).
Concert Pharmaceuticals Inc.
Edwards Angell Palmer & Dodge
Hsi Jeffrey D.
Russett Mark D.
Ward Paul V.
LandOfFree
Substituted triazolo-pyridazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted triazolo-pyridazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted triazolo-pyridazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2680718